Prime Medicine (PRME) Return on Sales (2024 - 2026)

Prime Medicine has reported Return on Sales for 3 years, with the latest figure at 0.58% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales fell 22.0% year-over-year to 0.58%; the trailing twelve-month figure through Mar 2026 stood at 0.5% (up 2.0% YoY), and the FY2025 full-year result was 0.44%, up 22.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.58%, down from 0.57% in the prior quarter.
• The five-year high for Return on Sales was 0.19% in Q4 2024, with the low at 3.68% in Q2 2024.
• Historically, Return on Sales has averaged 1.06% across 3 years, with a median of 0.57% in 2025.
• The largest YoY upside for Return on Sales was 321 bps in 2025 against a maximum downside of 37 bps in 2025.
• Prime Medicine's Return on Sales stood at 0.19% in 2024, then sank by 193 bps to 0.57% in 2025, then declined by 2 bps to 0.58% in 2026.
• The last three Return on Sales figures came in at 0.58% (Q1 2026), 0.57% (Q4 2025), and 0.43% (Q3 2025), per Business Quant data.